effect of aromatase inhibitors on bones and genes

Conditions: Breast Cancer; Postmenopausal

Summary: the primary objective of this 2-year pilot project is to test the hypothesis that skeletal response to aromatase inhibitors is determined by polymorphisms of the cyp19 gene.

a family history of osteoporosis will be noted. data on the factors that affect estrogen exposure such as age at menarche, average number of periods per year during the reproductive years, number of years of birth control pill use, total number of pregnancies, number of pregnancies to term, months of lactation and age at menopause will be recorded. these data will be collected at baseline. current medications and other medical problems will be recorded at baseline and during follow-up visits. new medical problems and new medications will be noted on follow-up. physical examination will be done at baseline and during follow-up visits. body mass index calculated as weight (kg) divided by the square of the height (m2) will be obtained every visit. height will be obtained using a standard stadiometer and weight will be taken using a standard weighing scale. dietary calcium and vitamin d intake will be estimated from a 7-day dietary recall at baseline and adjusted to a daily intake of 1200-1500 mg of calcium per day. vitamin d intake will also be adjusted to 800 iu per day. biochemical analysis. routine serum comprehensive metabolic profile (cmp) will be measured by standard autoanalyzer technique, serum 25-hydoxyvitamin d by double-antibody radioimmunoassay (incstar corp., stillwater, minnesota), and fsh by chemiluminescent assay (bayer, ny) in those cases when the last menstrual period occurred less than 12 months before the signing of the informed consent. these measurements will be done through the barnes-jewish hospital laboratory. serum estradiol will be measured by radioimmunoassay (diagnostic systems laboratories inc.), and sex hormone binding globulin by double antibody radioimmunoassay (diagnostic laboratories inc). serum estradiol measurements will be done at the core laboratory of the general clinical research center (gcrc) of washington university school of medicine while the sex hormone binding globulin assay will be done at dr. villareal's laboratory. the inter- and intra-assay coefficients of variation for these assays are all \< 10%. in order to improve accuracy of the analysis the biochemical tests (except for 25-oh vitamin d) will be performed at the end of the study and will be run by the same operator and plate (run in batch). bone mineral density (bmd) bmd of the total body, lumbar spine and the proximal left femur will be measured by dual energy x-ray absorptiometry (dexa) using hologic qdr 4500 (hologic inc., waltham ma, u.s.a.). measurements will be done at month 0, 6 and 12 (see visits and testing schedule). to guarantee the necessary flexibility for the patients who can not be seen at the exact date for the follow up a window of 1 month earlier and 2 months of late will be considered. bmd of the lumbar spine will be measured from l1 to l4. the non-dominant hip will be used for studies on the proximal femur. the main regions of interest on the proximal femur will be the total femur, femoral neck and femoral trochanter. the coefficient of variability for these repeated measurements in our institution is1.09% for the lumbar spine and 1.2% for the total femur in our center. bone turnover markers will be obtained at month 0, 6 and 12. we will follow a marker of bone resorption (urine cross-linked n- telopeptide of type i collagen \[urine ntx\] or, when a proper 24 hour urine collection is not done, serum cross-linked telopeptide of type i collagen \[serum ctx) will be analyzed) and one marker of bone formation (serum bone specific alkaline phosphatase {bsap). due to the diurnal pattern of bone markers, all serum specimens will be collected in the fasting state while urinary ntx will measured on 24-hour urine collection. these markers will be measured by elisa at the core laboratory for clinical studies at washington university as follows: urine ntx (osteomark, ostex international, inc., seattle, wa), serum ctx (serum crosslaps, osteometer, hawthorne, ca) and serum bsap (alkphase-b, metra biosystems, inc., mountain view, ca). intra-assay coefficients of variations are in the range of 4-7% (32;33). in order to improve accuracy of the analysis biochemical tests will be performed at the end of the study and will be run by the same operator and plate (conducted in batch). vertebral fracture evaluation. we will evaluate vertebral fractures using the vertebral fracture assessment (vfa) method performed by the same dexa machine used to measure the bone mineral density. those patients whose vfa is suspicious for a fracture will undergo a lateral spine x-ray. vertebral fractures will be identified by visual inspection of lateral spine radiographs of the thoracic and lumbar vertebrae, from t4 to l5. interpretation of radiographs will be done by the pi, who is an endocrinologist specializing in bone disease and the medical director of the bone health program in the division of bone and mineral diseases at washington university school of medicine. if the pi will have some doubts, she can easily ask the opinion from the bone radiologists at the department of radiology at washington university school of medicine. menopausal symptom evaluation. symptoms related to menopause will be evaluated using a modified leuven menopause questionnaire. this is a straightforward menopause-specific questionnaire which covers vasomotor, gynecologic, psychological, cognitive and somatic symptoms which was developed and validated in a previous study (anti-cancer drugs 2004 15:753-760). the leuven questionnaire includes definitions of each menopausal symptoms and rated as: 1 (no symptom), 2 (mild) up to 5 (intolerable). this questionnaire will be administered at month 0, 3, 6 and 12. this questionnaire will be administered during the patient visits at month 0, 6 and 12, and it will be sent by mail approximately two weeks prior to month 3. a phone call will also be made to the patients to prompt them to complete the questionnaire approximately at the time they should receive it by mail (month 3). those who will fail to send the questionnaire within 1 week after the indicated dates will be contacted by phone. a log will be kept to document phone call attempts and dates of mailings to document persistence with compliance. a symptom score will be estimated for each participant. the number of symptomatic subject in each genotype will also be estimated. psychometric testing: in the current project we will assess the cognitive impairment using the mini mental state examination test (normal range of \> 72 for women \ 76 for those who have \> 9 years of formal education) and attention and executive functions using trail making tests a and b (the score is the number of seconds spent in connecting 25 numbered circles in sequential order \[trail a\] or the seconds spent in connecting numbered circles (1-13) alternately to letters of the alphabet (a-l) in sequential order \[trail b\]. in both tests a maximum of 180 seconds is allowed). a fluency test will be performed asking to the subjects to name as many animals as they can during 1 minute. additionally the geriatric depression scale (gds) will be performed in order to exclude and to assess eventual depression. this test implies 30 questions, each one corresponding to a score of 0 or 1. according to the final score a patient is classified normal with a score ranging from 0 to 9, mildly depressed if from 10 to 20, and severely depressed if the score is higher than 20. these tests will be administered during the patient visits at month 0, 6 and 12. rationale. to date, 4 polymorphisms of the aromatase gene have been associated with significant differences in bmd and fracture risk (16-18), age-related bone loss (18;29) a few of which have also been found to be associated with differences in breast cancer risk (30). functional in-vitro analysis suggests an altered enzymatic activity in certain variants for this gene perhaps accounting for differences in the risk of breast cancer and osteoporosis. variants with increased aromatase activity (18), as in those with higher number of ttta repeats, have higher bmd but higher risk for breast cancer (30) possibly a consequence of higher estrogen levels. because these variants have increased enzyme activity, it is possible that this select group of women will have increased sensitivity to aromatase inhibition and would experienced more bone loss than those with lower aromatase activity. on the contrary, it is also possible that women with these variant alleles will be relatively resistant to aromatase inhibition compared to variants with lower enzymatic activity and will continue to synthesize estrogen from precursors and, therefore, will not develop rapid bone loss. this proposal will address this important question by comparing the variants of the different polymorphisms described below.

Eligibility criteria:
inclusion criteria: * postmenopausal women aged greater than or equal to 40 years, at least 12 months from last menstrual period. for subjects who are amenorrheic for \< 12 months (including patients who had hysterectomy, received ert/hrt, or rendered amenorrheic by chemotherapy), they must have serum fsh =50 ui/l. * must have diagnosis of breast cancer stages i-iiia. * planned therapy for the treatment group must include aromatase inhibitors using third generation non-steroidal aromatase inhibitors, anastrozole or letrozole. those who are already treated with aromatase inhibitors and have bone density measurements prior to initiation of aromatase inhibitors or will be switched from tamoxifen to third generation aromatase inhibitors will also be included in the study. * bone mineral density measurement must range from normal to osteopenia (t-scores between +2.0/-2.0). those with t-scores of \<-2.0 in either the lumbar spine or the femoral neck as well as those with a history of osteoporosis-related fractures or vertebral deformities on lateral spine radiographs will be excluded from the study. * must be ambulatory willing and able to provide informed consent. exclusion criteria: * no current use of medications affecting bone metabolism, namely: estrogen, raloxifene, tamoxifen, bisphosphonates, gnrh analogues, glucocorticoids of at least 5 mg daily for 1 month or more, anabolic steroids and dilantin. * no evidence of diseases known to interfere with bone metabolism, such as hyperparathyroidism, hyperthyroidism, osteomalacia, chronic liver disease, renal failure, hypercortisolism, malabsorption, and immobilization. * no current alcohol or tobacco abuse. * no evidence of bone metastasis or evidence of abnormal clinical laboratory parameters that are assessed as clinically significant by the investigator.

Keywords: breast cancer postmenopausal aromatase